Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.

Susawa, Takashi; YUl, Yoshiki; Hattori, Ryuichi; Takatsu, Yoshiki; YUl, Natsuko; Takahashi, Mamoru; Aoyama, Takeshi; Murohara, Yoshiharu; Shirotani, Manabu; Kawai, Chuichi

doi:10.1253/jcj.52.72

Search citation statements

Order By: Relevance

Paper Sections

Select...

Drug and Dosage Considerations1

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1991

1997

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rationale for systemic heparinization includes prevention of pericatheter thrombus formation, prevention of propagating thrombosis distal to an occlusion in an acutely occluded segment, and the possible potentiation of fibrinolytic activity with heparin. [26][27][28]53,54 In less severely ischemic limbs, low-dose regional heparinization (200 to 400 U/hr) is an alterative that accomplishes the same objectives with fewer risks. 25 With severe ischemia, there is greater risk of propagating thrombus, and systemic heparinization should be used.…”

Section: Drug and Dosage Considerationsmentioning

confidence: 99%

Thrombolysis in Arterial Bypass Grafts

1991

Semin Thromb Hemost

View full text Add to dashboard Cite

Section: Drug and Dosage Considerationsmentioning

confidence: 99%

Thrombolysis in Arterial Bypass Grafts

1991

Semin Thromb Hemost

View full text Add to dashboard Cite

“…Until now, however, only the enhancement of thrombolysis by heparin has been demonstrated in animal experiments [7][8][9]. In contrast, the thera peutic value of heparin in the prevention of reocclusion has not been proven.…”

Section: Introductionmentioning

confidence: 99%

Effect of Recombinant Hirudin (LU 52369) on Reocclusion Rates after Thrombolysis in Rabbits

Rübsamen¹,

Eschenfelder²

1991

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

The effect of recombinant hirudin (r-hirudin, LU 52369) and unfractionated heparin on recombinant tissue-type plasminogen activator (rt-PA; LU 50232) thrombolysis and reocclusion rates after successful thrombolysis was studied in a copper-coil-induced thrombus model in the iliac artery of anesthetized rabbits. Simultaneous administration of rt-PA and recombinant hirudin (r-hirudin) at a dose not affecting the partial thromboplastin time (PTT) increased the number of recanalized arteries significantly. The incidence of reocclusion was drastically reduced from 100% to less than 25%. At a dose increasing PTT twofold, unfractionated heparin had no effect on the incidence of reperfusion and reocclusion. These experimental data indicate that the combination of rt-PA with low-dose r-hirudin may be useful for the prevention of early reocclusion in thrombolytic therapy.

show abstract

Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis

Schneider

1991

Thrombosis Research

View full text Add to dashboard Cite

Enhancement of coronary thrombolysis with plasminogen pro-activator by pretreatment with heparin.

Cited by 5 publications

References 19 publications

Thrombolysis in Arterial Bypass Grafts

Thrombolysis in Arterial Bypass Grafts

Effect of Recombinant Hirudin (LU 52369) on Reocclusion Rates after Thrombolysis in Rabbits

Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis

Contact Info

Product

Resources

About